Credit Suisse’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,347
| Closed | -$54.5K | – | 3059 |
|
|
2023
Q3 | $54.5K | Sell |
1,347
-619
| -31% | -$25.1K | ﹤0.01% | 3106 |
|
|
2023
Q2 | $209K | Buy |
1,966
+843
| +75% | +$89.8K | ﹤0.01% | 3073 |
|
|
2023
Q1 | $335K | Buy |
1,123
+249
| +28% | +$74.3K | ﹤0.01% | 2933 |
|
|
2022
Q4 | $300K | Sell |
874
-9
| -1% | -$3.09K | ﹤0.01% | 3028 |
|
|
2022
Q3 | $167K | Buy |
883
+5
| +0.6% | +$946 | ﹤0.01% | 3289 |
|
|
2022
Q2 | $185K | Sell |
878
-28
| -3% | -$5.9K | ﹤0.01% | 3341 |
|
|
2022
Q1 | $303K | Buy |
906
+58
| +7% | +$19.4K | ﹤0.01% | 3202 |
|
|
2021
Q4 | $276K | Buy |
848
+4
| +0.5% | +$1.3K | ﹤0.01% | 3326 |
|
|
2021
Q3 | $410K | Buy |
844
+66
| +8% | +$32.1K | ﹤0.01% | 3112 |
|
|
2021
Q2 | $361K | Hold |
778
| – | – | ﹤0.01% | 3187 |
|
|
2021
Q1 | $537K | Sell |
778
-2,269
| -74% | -$1.57M | ﹤0.01% | 2912 |
|
|
2020
Q4 | $2.25M | Sell |
3,047
-664
| -18% | -$491K | ﹤0.01% | 2051 |
|
|
2020
Q3 | $2.57M | Buy |
3,711
+712
| +24% | +$494K | ﹤0.01% | 1655 |
|
|
2020
Q2 | $2.54M | Buy |
+2,999
| New | +$2.54M | ﹤0.01% | 1693 |
|